Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Arthritis Research and Therapy

Volumn 19, Issue 1, 2017, Pages

  Ishizaki, Jun ^a   Takemori, Ayako ^b   Suemori, Koichiro ^a   Matsumoto, Takuya ^a   Akita, Yoko ^a   Sada, Ken ei ^c   Yuzawa, Yukio ^d   Amano, Koichi ^e   Takasaki, Yoshinari ^f   Harigai, Masayoshi ^g   Arimura, Yoshihiro ^h   Makino, Hirofumi ⁱ   Yasukawa, Masaki ^a   Takemori, Nobuaki ^b   Hasegawa, Hitoshi ^a   Murakawa, Yohko ^j   Muso, Eri ^k   Komatsuda, Atsushi ^l   Ito, Satoshi ^m   Fujii, Takao ⁿ   Kawakami, Atsushi ^o   Nakaya, Izaya ^p   Saito, Takao ^q   Ito, Takafumi ^j   Hirawa, Nobuhito ^r   Yamamura, Masahiro ^s   Nakano, Masaaki ^t   Nitta, Kosaku ^g   Ogura, Makoto ^u   Naniwa, Taio ^v   Ozaki, Shoichi ^w   Hirahashi, Junichi ^x   Ogawa, Noriyoshi ^y   Hosoya, Tatsuo ^z   Wada, Takashi ^aa   Horikoshi, Satoshi ^ab   Kawaguchi, Yasushi ^g   Hayashi, Taichi ^ac   Yoshida, Masaharu ^ad   Watanabe, Tsuyoshi ^ae   Inaguma, Daijo ^af   Tsuruya, Kazuhiko ^ag   Homma, Noriyuki ^ah   Takeuchi, Tsutomu ^ai   Nakagawa, Naoki ^aj   Takeda, Shinichi ^ak   Katabuchi, Ritsuko ^al   Iwano, Masayuki ^am   Atsumi, Tatsuya ^an   Fujimoto, Shoichi ^ao   Banno, Shogo ^ap   Sugihara, Takahiko ^aq   Kobayashi, Masaki ^ar   Yamagata, Kunihiro ^ac   Homma, Sakae ^as   Dobashi, Hiroaki ^at   Tsuboi, Naotake ^au   Ishizu, Akihiro ^av   Sugiyama, Hitoshi ^c   more..

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f Juntendo University Hospital   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^j SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^k Kitano Hospital   (Japan)

^l AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m Niigata Rheumatic Center   (Japan)

ⁿ KYOTO UNIVERSITY   (Japan)

^o NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^p Iwate Prefectural Central Hospital   (Japan)

^q FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^s OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^t NIIGATA UNIVERSITY   (Japan)

^u JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^v NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^w ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^x UNIVERSITY OF TOKYO   (Japan)

^y HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^z JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^aa KANAZAWA UNIVERSITY   (Japan)

^ab JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ac UNIVERSITY OF TSUKUBA   (Japan)

^ad TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^ae FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^af NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^ag KYUSHU UNIVERSITY   (Japan)

^ah Niigata Prefectural Shibata Hospital   (Japan)

^ai KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^aj ASAHIKAWA MEDICAL COLLEGE   (Japan)

^ak Kurobe City Hospital   (Japan)

^al FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^am UNIVERSITY OF FUKUI   (Japan)

^an HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ao UNIVERSITY OF MIYAZAKI   (Japan)

^ap AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^aq Tokyo Metropolitan Institute of Gerontology   (Japan)

^ar TOKYO MEDICAL UNIVERSITY   (Japan)

^as TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^at KAGAWA UNIVERSITY   (Japan)

^au NAGOYA UNIVERSITY HOSPITAL   (Japan)

^av HOKKAIDO UNIVERSITY   (Japan)

more..

Author keywords

Antineutrophil cytoplasmic antibody associated vasculitis; Biomarkers; Eosinophilic granulomatosis with polyangiitis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Targeted proteomics

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN A; CALGRANULIN B; CD93 ANTIGEN; GELATINASE B; GLYCOPROTEIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN 1; LYMPHOCYTE ANTIGEN; MYELOPEROXIDASE NEUTROPHIL CYTOPLASMIC ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSKETOLASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENERAL ASPECTS OF DISEASE; HUMAN; JAPANESE (PEOPLE); LIQUID CHROMATOGRAPHY; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NANOFLOW LIQUID CHROMATOGRAPHY; ORGAN INVOLVEMENT; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REMISSION; SELECTED REACTION MONITORING MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TARGETED PROTEOMICS; VALIDATION PROCESS; BLOOD; MIDDLE AGED; PROCEDURES;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS;

EID: 85030253143     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-017-1429-3     Document Type: Article

References (59)

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
2. Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis (Basel). 2016;1(4):205-15.
3. Falk RJ, Hoffman GS. Controversies in small vessel vasculitis - comparing the rheumatology and nephrology views. Curr Opin Rheumatol. 2007;19(1):1-9.
4. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025-33.
5. Girard T, Mahr A, Noël LH, Cordier JF, Lesavre P, André MH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford). 2001;40(2):147-51.
6. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis. 2006;47(1):15-23.
7. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford). 2012;51(1):100-9.
8. Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, et al. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2011;63(12):3988-97.
9. Monach PA, Warner RL, Tomasson G, Specks U, Stone JH, Ding L, et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis. 2013;72(8):1342-50.
10. Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83(1):129-37.
11. Brix SR, Stege G, Disteldorf E, Hoxha E, Krebs C, Krohn S, et al. CC chemokine ligand 18 in ANCA-associated crescentic GN. J Am Soc Nephrol. 2015;26(9):2105-17.
12. Villacorta J, Diaz-Crespo F, Acevedo M, Cavero T, Guerrero C, Praga M, et al. Circulating C3 levels predict renal and global outcome in patients with renal vasculitis. Clin Rheumatol. 2016;35(11):2733-40.
13. Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, et al. The association of serum calprotectin (S100A8/S100A9) levels with disease relapses in PR3-ANCA-associated vasculitis. Arthritis Rheumatol. 2016;69(1):185-93.
14. Kronbichler A, Kerschbaum J, Gründlinger G, Leierer J, Mayer G, Rudnicki M. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant. 2016;31(6):930-6.
15. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9(6):555-66.
16. Hüttenhain R, Soste M, Selevsek N, Röst H, Sethi A, Carapito C, 142, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4:142ra94.
17. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2013;10(1):28-34.
18. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods. 2014;11(2):149-55.
19. Surinova S, Choi M, Tao S, Schüffler PJ, Chang CY, Clough T, et al. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med. 2015;7(9):1166-78.
20. Surinova S, Radová L, Choi M, Srovnal J, Brenner H, Vitek O, et al. Non-invasive prognostic protein biomarker signatures associated with colorectal cancer. EMBO Mol Med. 2015;7(9):1153-65.
21. Takemori N, Takemori A, Matsuoka K, Morishita R, Matsushita N, Aoshima M, et al. High-throughput synthesis of stable isotope-labeled transmembrane proteins for targeted transmembrane proteomics using a wheat germ cell-free protein synthesis system. Mol Biosyst. 2015;11(2):361-5.
22. Kim Y, Jeon J, Mejia S, Yao CQ, Ignatchenko V, Nyalwidhe JO, et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun. 2016;7:11906.
23. Kusebauch U, Campbell DS, Deutsch EW, Chu CS, Spicer DA, Brusniak MY, et al. Human SRMAtlas: a resource of targeted assays to quantify the complete human proteome. Cell. 2016;166(3):766-78.
24. Takemori N, Takemori A, Tanaka Y, Ishizaki J, Hasegawa H, Shiraishi A, et al. High-throughput production of a stable isotope-labeled peptide library for targeted proteomics using a wheat germ cell-free synthesis system. Mol Biosyst. 2016;12(8):2389-93.
25. Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, et al. Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2016;26(5):730-7.
26. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-7.
27. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum. 2010;62(9):2582-91.
28. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-57.
29. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
30. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002;29(2):288-91.
31. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827-32.
32. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605-17.
33. Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13(6):633-50.
34. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19-27.
35. Takemori N, Takemori A, Ishizaki J, Hasegawa H. Enzymatic protein digestion using a dissolvable polyacrylamide gel and its application to mass spectrometry-based proteomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;967:36-40.
36. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966-8.
37. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. 1998;14(8):656-64.
38. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248-50.
39. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, Mallick P, Eng J, et al. The PeptideAtlas project. Nucleic Acids Res. 2006;34(Database issue):D655-8.
40. Muthusamy B, Hanumanthu G, Suresh S, Rekha B, Srinivas D, Karthick L, et al. Plasma Proteome Database as a resource for proteomics research. Proteomics. 2005;5(13):3531-6.
41. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55-71.
42. Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014;71(4):659-72.
43. Garza MA, Wason EA, Zhang JQ. Cardiac remodeling and physical training post myocardial infarction. World J Cardiol. 2015;7(2):52-64.
44. Kim YS, Kim SH, Kang JG, Ko JH. Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression. BMB Rep. 2012;45(11):623-8.
45. Bjerkeli V, Halvorsen B, Damås JK, Nordøy I, Yndestad A, Aukrust P, et al. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis. Ann Rheum Dis. 2004;63(12):1659-63.
46. Kochetov GA, Solovjeva ON. Structure and functioning mechanism of transketolase. Biochim Biophys Acta. 2014;1844(9):1608-18.
47. Mitschke L, Parthier C, Schröder-Tittmann K, Coy J, Lüdtke S, Tittmann K. The crystal structure of human transketolase and new insights into its mode of action. J Biol Chem. 2010;285(41):31559-70.
48. Zhao J, Zhong CJ. A review on research progress of transketolase. Neurosci Bull. 2009;25(2):94-9.
49. Sax CM, Salamon C, Kays WT, Guo J, Yu FX, Cuthbertson RA, et al. Transketolase is a major protein in the mouse cornea. J Biol Chem. 1996;271(52):33568-74.
50. Greenlee-Wacker MC, Galvan MD, Bohlson SS. CD93: recent advances and implications in disease. Curr Drug Targets. 2012;13(3):411-20.
51. Greenlee MC, Sullivan SA, Bohlson SS. Detection and characterization of soluble CD93 released during inflammation. Inflamm Res. 2009;58(12):909-19.
52. Mälarstig A, Silveira A, Wågsäter D, Öhrvik J, Bäcklund A, Samnegård A, et al. Plasma CD93 concentration is a potential novel biomarker for coronary artery disease. J Intern Med. 2011;270(3):229-36.
53. Youn JC, Yu HT, Jeon JW, Lee HS, Jang Y, Park YW, et al. Soluble CD93 levels in patients with acute myocardial infarction and its implication on clinical outcome. PLoS One. 2014;9(5), e96538.
54. Fonseca MI, Carpenter PM, Park M, Palmarini G, Nelson EL, Tenner AJ. C1qR(P), a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue. J Leukoc Biol. 2001;70(5):793-800.
55. Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150-8.
56. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: from basic science to clinical application. Pharmacol Ther. 2016;167:120-31.
57. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009;3(3-4):287-310.
58. Kaarteenaho-Wiik R, Mertaniemi P, Sajanti E, Soini Y, Pääkkö P. Tenascin is increased in epithelial lining fluid in fibrotic lung disorders. Lung. 1998;176(6):371-80.
59. Kaarteenaho-Wiik R, Lakari E, Soini Y, Pöllänen R, Kinnula VL, Pääkkö P. Tenascin expression and distribution in pleural inflammatory and fibrotic diseases. J Histochem Cytochem. 2000;48(9):1257-68.